10月5日，默沙东盘中下跌3.13%，报139.75美元。
消息面上尽管盘中多家投行机构上调目标价，但抛压情绪占据上风。JP摩根当日将默沙东目标价从150美元上调至165美元；稍早前Jefferies和Scotiabank也已分别将目标价调升至177美元和180美元并维持买入评级。市场短线获利盘可能在利好集中兑现后增加。
默克制药公司于1970年在新泽西州注册成立，是一家全球医疗保健公司，通过其处方药提供创新的健康解决方案，包括生物疗法、疫苗和动物保健产品。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.